We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $46.02, marking a -1.03% move from the previous day. This move lagged the S&P 500's daily gain of 0.05%. At the same time, the Dow added 0.26%, and the tech-heavy Nasdaq gained 0.3%.
Heading into today, shares of the biopharmaceutical company had lost 6.74% over the past month, lagging the Medical sector's loss of 3.78% and the S&P 500's gain of 3.08% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be April 25, 2019. In that report, analysts expect BMY to post earnings of $1.06 per share. This would mark year-over-year growth of 12.77%. Our most recent consensus estimate is calling for quarterly revenue of $5.80 billion, up 11.67% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.16 per share and revenue of $23.86 billion. These totals would mark changes of +4.52% and +5.75%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BMY is holding a Zacks Rank of #4 (Sell) right now.
Looking at its valuation, BMY is holding a Forward P/E ratio of 11.18. This valuation marks a discount compared to its industry's average Forward P/E of 15.02.
Meanwhile, BMY's PEG ratio is currently 2.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 2.14 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $46.02, marking a -1.03% move from the previous day. This move lagged the S&P 500's daily gain of 0.05%. At the same time, the Dow added 0.26%, and the tech-heavy Nasdaq gained 0.3%.
Heading into today, shares of the biopharmaceutical company had lost 6.74% over the past month, lagging the Medical sector's loss of 3.78% and the S&P 500's gain of 3.08% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be April 25, 2019. In that report, analysts expect BMY to post earnings of $1.06 per share. This would mark year-over-year growth of 12.77%. Our most recent consensus estimate is calling for quarterly revenue of $5.80 billion, up 11.67% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.16 per share and revenue of $23.86 billion. These totals would mark changes of +4.52% and +5.75%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BMY is holding a Zacks Rank of #4 (Sell) right now.
Looking at its valuation, BMY is holding a Forward P/E ratio of 11.18. This valuation marks a discount compared to its industry's average Forward P/E of 15.02.
Meanwhile, BMY's PEG ratio is currently 2.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 2.14 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.